Implications of the FDA approval of PCSK9 inhibitors and FOURIER results for contemporary cardiovascular practice: An NCDR Research to Practice (R2P) project

Paul L. Hess, Kevin Kennedy, Michael Cowherd, Salim S. Virani, Frederick A. Masoudi, Ann Marie Navar, Robert W. Yeh, P. Michael Ho, Thomas M. Maddox

Research output: Contribution to journal › Letter › peer-review

12 Scopus citations

Fingerprint

Dive into the research topics of 'Implications of the FDA approval of PCSK9 inhibitors and FOURIER results for contemporary cardiovascular practice: An NCDR Research to Practice (R2P) project'. Together they form a unique fingerprint.